Publications

The International Prophylaxis Study Group (IPSG) is committed to advancing hemophilia research through peer-reviewed publications, clinical studies, and scientific presentations. Our work focuses on prophylaxis, pharmacokinetics, imaging, musculoskeletal health, and access to care, with the goal of improving treatment strategies and patient outcomes.
Below is a collection of IPSG-authored and collaborative publications, including studies on long-term prophylaxis, outcome measurement tools, and innovative treatment approaches. These resources serve as valuable references for clinicians, researchers, and healthcare policymakers worldwide.
Use of ultrasound for assessment of musculoskeletal disease in persons with hemophilia: Results of an International Prophylaxis Study Group (IPSG) survey.
Authors
Doria AS, von Drygalski A, Blanchette VS, Chang EY, Dover S, Fischer K, Sridhar G, Shyamkumar K, Querol F, Babyn P.
Citation
Haemophilia 2018; 24 (S5): 391, W- P- 085
Elevated HJHS Scores in healthy adult males without hemophilia
Authors
Feldman B, Zourikian N, Funk S, Tilak M, Lobet S, Manco-Johnson M, Srivastava A, Hilliard P, Tiseo L and St-Louis J
Citation
Haemophilia 2018; 24 (S5): 176, W- FPMED01- 002
An International Prophylaxis Study Group (IPSG) survey of prophylaxis in inhibitor positive children/adults with severe haemophilia
Authors
Carcao MD, Avila L, Leissinger C, Blanchette VS, Aledort L; Factor Utilization Expert Working Group on behalf of the International Prophylaxis Study Group (IPSG) and participating Survey Investigators.
Citation
Haemophilia 2017; 23 (5) : e444 - e447
An International Prophylaxis Study Group (IPSG) survey of prophylaxis in adults with severe haemophilia
Authors
Carcao M, Avila L, Leissinger C, Blanchette VS, and Aledort LM on behalf of the Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and participating Survey Investigators
Citation
Haemophilia 2017; 23 (5):e447 - e450
Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates
Authors
Iorio A, K. Fischer BM, Blanchette V, Rangarajan S, Young G, Morfini M, for the Pharmacokinetic (PK) Expert Working Group of the International Prophylaxis Study Group (the IPSG)
Citation
Thrombosis and Haemostasis 2017; 117 (6): 1023 - 1030
Securing reimbursement for patient centered haemophilia care: major collaborative efforts are needed.
Authors
Berger K, Feldman BM, Wasserman J, Schramm W, Blanchette VS, Fischer K on behalf of the Outcome Measures Expert Working Group of the IPSG
Citation
Haematologica; March 2016 101: 266-268
Hemophilia prophylaxis no longer just for children without inhibitors – increasing use of prophylaxis in other groups (children with inhibitors and adults with and without inhibitors).
Authors
Carcao M, Avila L, Blanchette V, Santagostino E, Escuriola-Ettingshausen C, Leissinger C, Lambert T, Aledort L on behalf of the International Prophylaxis Study Group (IPSG) and Survey Investigators
Citation
57th American Society of Hematology Meeting 2015.
Hemophilia prophylaxis no longer just for children without inhibitors – increasing use of prophylaxis in other groups (children with inhibitors and adults with and without inhibitors)
Authors
Carcao M, Avila L, Blanchette V, Santagostino E, Escuriola-Ettingshausen C, Leissinger C, Lambert T, Aledort L on behalf of the International Prophylaxis Study Group (IPSG) and Survey Investigators.
Citation
Blood 2015; 126: 3535
Prophylaxis in adult patients with severe hemophilia A or B without inhibitors.
Authors
Carcao, M on behalf of Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and other Survey Investigators.